The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
Patients with colorectal cancer and diabetes have better survival with adherence to diabetes meds.
At week 10, filgotinib 200mg met the primary end point with a significantly higher proportion of patients achieving clinical remission compared with placebo.
The FDA has approved Qinlock™ (ripretinib; Deciphera) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
Pemigatinib, a small molecule kinase inhibitor, selectively targets FGFR isoforms 1, 2 and 3, which, in preclinical studies, has resulted in anti-tumor activity in cells with FGFR alterations.
Ontruzant is supplied in 150 mg single-dose vials and 420 mg multidose vials.
The FDA has approved the therascreen® BRAF V600E RGQ PCR Kit (Qiagen) as a companion diagnostic to help identify metastatic colorectal cancer patients eligible for treatment with Braftovi® (encorafenib; Pfizer) in combination with cetuximab.
The application is supported by data from 2 pivotal open-label, randomized phase 3 trials (SIOPEL 6 and ACCL0431), which compared the efficacy of sodium thiosulfate plus cisplatin to cisplatin alone for the prevention of cisplatin-induced hearing loss.
The FDA has approved Braftovi® (encorafenib; Pfizer) in combination with cetuximab (Erbitux®; Lilly) for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.
